Division of Medical Oncology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
JAMA Oncol. 2021 Dec 1;7(12):1882-1890. doi: 10.1001/jamaoncol.2021.4083.
The COVID-19 pandemic has had consequences for patients with cancer worldwide and has been associated with delays in diagnosis, interruption of treatment and follow-up care, and increases in overall infection rates and premature mortality.
Despite the challenges experienced during the pandemic, the global oncology community has responded with an unprecedented level of investigation, collaboration, and technological innovation through the rapid development of COVID-19 registries that have allowed an increased understanding of the natural history, risk factors, and outcomes of patients with cancer who are diagnosed with COVID-19. This review describes 14 major registries comprising more than 28 500 patients with cancer and COVID-19; these ongoing registry efforts have provided an improved understanding of the impact and outcomes of COVID-19 among patients with cancer.
An initiative is needed to promote active collaboration between different registries to improve the quality and consistency of information. Well-designed prospective and randomized clinical trials are needed to collect high-level evidence to guide long-term epidemiologic, behavioral, and clinical decision-making for this and future pandemics.
COVID-19 大流行对全球癌症患者产生了影响，并与诊断延迟、治疗和随访护理中断、总感染率增加以及过早死亡率升高有关。
尽管在大流行期间面临挑战，但全球肿瘤学界通过快速开发 COVID-19 登记处，以空前的调查、合作和技术创新做出了回应，这使得人们对确诊 COVID-19 的癌症患者的自然史、风险因素和结果有了更多的了解。本综述描述了由超过 28500 名癌症和 COVID-19 患者组成的 14 个主要登记处；这些正在进行的登记处工作提供了对癌症患者中 COVID-19 的影响和结果的更好理解。
需要采取主动措施，促进不同登记处之间的积极合作，以提高信息的质量和一致性。需要精心设计前瞻性和随机临床试验，以收集高水平证据，为未来的大流行和未来的大流行指导长期的流行病学、行为和临床决策。
